



Startup Shield SPV.

Steve Rhodes
Chair and CEO

Todd Dollinger
Chair and CEO

Haim Brosh
CFO

Q4 2023



Why and how.

Why

2023 was going to be tough for raising funds. With the recent terrorist attacks on Israel, it's much worse; investors are even more cautious. They want to "wait and see." **Our companies cannot wait and see.**

With the war, companies raising funds are further challenged: they cannot travel, many are on emergency army duty. Companies will struggle to survive to better times. **They need us now.**

Great investment potential. **Outstanding companies + discounted valuations = tremendous opportunity.**

How

Trendlines has established **Startup Shield SPV**, an Israeli limited partnership, to help bridge outstanding companies to better investment times.

Startup Shield is extending the financial runways of otherwise strong companies, allowing them to survive, progress, and be **positioned to raise additional capital in better market conditions.**

Startup Shield.

Startup Shield investments:

- Aiming to invest in ~15 – 20 Trendlines portfolio companies
- Per company investment: ~\$250,000 - \$1,000,000, for minimum 12 months' runway
- Invest in SAFE instruments (convertible instruments, valuation a discount of next round), or rounds led by 3rd parties.







Your investment in the Startup Shield SVP:

- Minimum limited partner investment: \$75,000; 100% due at closing
- No fees to Trendlines – no management fee or carried interest
- Trendlines to bear all organizational expenses other than legal and placement agent fees
- Ongoing expenses limited to accounting, audit, and legal
- Semi-annual reports, audited annual financial reports, and K-1s will be provided to the investors
- Investment is for accredited investors only

Selected
potential investee
portfolio
companies.









Potential **Startup Shield** companies

	AI-based autonomous agronomy	2023 sales > \$1 million
	Patented aquaculture water treatment	2023 sales ~ \$500k
	Coral-based bone substitutes	Successful 180-patient clinical trial
	Biological crop disease control	Successful field trials, 100% sustainable
	Home dialysis	FDA clearance received
	Precision biopsies	FDA clearance & breakthrough status received

**Click on company names to go to their individual websites

Potential **Startup Shield** companies

 METOMOTION	Greenhouse harvesting robots	7 systems sold in 2023
 ProArc Clearing the BPH path	Minimally invasive BPH treatment	In clinical trials
 SOLCHIP	Solar IoT tech for ag and proptech	2023 sales ~ \$750k
 SetBone medical	Breakthrough non-toxic bone cement	Clinical trials H1 2024
 ststent Short Term Stent Technology	Nasal stent to prevent revision surgery	FDA clearance received, initial sales
 ZYGOFIX	Minimally invasive spinal fusion	CE (European) clearance received

**Click on company names to go to their individual websites

Examples of
potential investee
portfolio
companies



AI-based crop monitoring.

AgroScout employs military AI concepts to make crops healthier, larger, and more sustainable by collecting and integrating data from multiple sources (field, air, space) for supply actionable insights

Achievements

- 2022: launched global sales
- Partnered with global players: Kraft Heinz, Mondelez, Adama, PepsiCo, DJI, AECI
- October 2023: Dr. Christine Daugherty, PepsiCo VP of Sustainable Agriculture, joined as chair
- Expected 2023 sales > \$1 million



Digital dialysis clinic.

All-in-one portable digital dialysis clinic, allowing peritoneal dialysis (PD) anywhere, safely, simply, and effectively

Achievements

- FDA Clearance
- Successful FIH clinical study
- 1st prize in the 100k MedTech Startup Contest
- \$2 million Horizon 2020 grant
- Chair: **Caroll Neubauer**, former Chair & CEO, B. Braun USA




Advanced greenhouse robotic systems.

The Greenhouse Robotic Worker (GRoW) platform harvests greenhouse crops and analyzes data for yield estimation and stress detection, reducing reliance on manual labor

Achievements

- Launched sales in Europe and China
- Strategic partnership with major high-tech greenhouses Dutch company
- Demo center established in greenhouse of Axia Vegetable Seeds
- European Union grant funding



MetoMotion's greenhouse tomatoes robotic harvester



Who **we** are.

Trendlines is an Israel-based company trading in Singapore on the SGX (42T) and in the USA on the OTCQX (TRNLY).



We invest in agrifood and medtech innovation to improve the human condition.

16

years' investment
and company
building experience

54*

portfolio
companies

20

advanced-stage
companies

10

exits

* including consolidated portfolio companies

9.7X return and 175% IRR on exits

Equity US\$104 million (30.06.2023)

Leadership.



Todd Dollinger
Chair and CEO

Trendlines' Founder; over 40 years' experience developing innovative products from concept to exit



Steve Rhodes
Chair and CEO

Trendlines' Founder; over 40 years' experience, deep understanding of investing and building companies



Haim Brosh
CFO

20 years' managerial and financial experience in public and private companies



Nitza Kardish PhD
CEO
Trendlines Agrifood

Vast experience in food and agriculture technologies alongside strong business acumen



Barak Singer
CEO
Trendlines Investments
Israel

Extensive investment knowledge & experience + strong managerial and business capabilities



Eric Loh
CEO
Trendlines Medical
Singapore

Over 30 years' experience establishing companies and leading their development



Kobby Greenberg
CEO
Trendlines Innovation
Labs

Brings a wealth of experience in the medical device industry

Weathering the Storm.

In Hebrew, there is a saying that literally translates as *“putting your shoulder under the stretcher.”* It’s about our pulling together to carry those who need help through difficult times.

Trendlines supports its companies. *We want to partner with you* to make sure that they can weather this storm to improve the human condition for us all.

Outstanding companies + discounted valuations = tremendous opportunity.

Join us.



Investing to improve
the human condition.

SGX: 42T
OTCQX: TRNLY

+972.72.260.7000
www.trendlines.com



Q4 2023

Steve Rhodes, Chair and CEO
steve@trendlines.com

Todd Dollinger, Chair and CEO
todd@trendlines.com

Haim Brosh, CFO
haim@trendlines.com

Legal disclaimer.

Important notice

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. ("Company") or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors and assumptions, such as known and unknown risks and uncertainties, including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNET. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its contents may be used without the prior written consent of the Company.